Stock Events

Stock Events

Idogen AB 

SEK0.120000
2
+SEK0.00+0%Thursday 08:00

Statistics

Day High
0.1205
Day Low
0.1205
52W High
0.1205
52W Low
0.12
Volume
1,133,255
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

May 12Expected
Q2 2020
Q3 2020
Q4 2020
Q2 2021
Q3 2021
Q4 2021
Q1 2022
-0.87
-0.67
-0.46
-0.25
Expected EPS
N/A
Actual EPS
-0.2496

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-47.75MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap518.24M
Allogene Therapeutics works on allogeneic CAR T therapies for cancer, directly competing with Idogen's immunological approach.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is involved in gene editing, a technology that is foundational to developing treatments like those Idogen is working on.
Intellia Therapeutics
NTLA
Mkt Cap1.72B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology space, relevant to Idogen's methodological approaches.
Fate Therapeutics
FATE
Mkt Cap277.98M
Fate Therapeutics works on programmed cellular immunotherapies for cancer and immune disorders, similar to Idogen's focus.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology and cell therapy space relevant to Idogen.
Pfizer
PFE
Mkt Cap158.45B
Pfizer, with its broad involvement in biopharmaceuticals including immunotherapy and oncology, indirectly competes across many of Idogen's interests.

About

Idogen AB (publ) is a Swedish biotechnology company specializing in the development of tolerogenic cell therapies. These innovative treatments are engineered to prevent a patient's immune system from attacking crucial elements, including biological agents, transplanted organs, and the body's own cells or tissues. The company's most advanced product in development is IDO 8, designed for individuals with severe haemophilia A who have developed neutralizing antibodies against their vital coagulation factor VIII treatment. Idogen is also developing IDO T, a tolerogenic cell therapy intended to prevent organ transplant rejection, primarily for kidney transplants, and IDO AID, aimed at treating autoimmune diseases. Established in 2008, the company is headquartered in Lund, Sweden.
Show More
CEO
Christina Herder
Employees
6
Country
Sweden
ISIN
SE0014428561

Listings

ST
SE
IDOGEN.ST

0 Comments

Share your thoughts

FAQs

What is Idogen AB stock price today?▼
The current price of IDOGEN.ST is SEK0.12 SEK — it has increased by +0% in the past 24 hours. Watch Idogen AB stock price performance more closely on the chart.
What is Idogen AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Idogen AB stocks are traded under the ticker IDOGEN.ST.
What were Idogen AB earnings last quarter?▼
IDOGEN.ST earnings for the last quarter are -0.25 SEK per share, whereas the estimation was N/A SEK resulting in a N/A surprise. The estimated earnings for the next quarter are N/A SEK per share.
What is Idogen AB revenue for the last year?▼
Idogen AB revenue for the last year amounts to 0 SEK.
What is Idogen AB net income for the last year?▼
IDOGEN.ST net income for the last year is -47.75M SEK.
How many employees does Idogen AB have?▼
As of November 2, 2026, the company has 6 employees.
In which sector is Idogen AB located?▼
Idogen AB operates in the Health & Wellness sector.
When did Idogen AB complete a stock split?▼
Idogen AB has not had any recent stock splits.
Where is Idogen AB headquartered?▼
Idogen AB is headquartered in Lund, Sweden.